Sartorius Stedim Biotech SA Total Assets
Sartorius Stedim Biotech SA total assets. Based on the latest financial reports, Sartorius Stedim Biotech SA (DIM) holds total assets worth €7.92 Billion EUR (≈ $9.26 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see DIM operating cash flow for how efficiently the company converts equity into cash flow.
Total Assets of Sartorius Stedim Biotech SA (2005–2025)
Total assets of Sartorius Stedim Biotech SA from 2005 to 2025. This chart illustrates how Sartorius Stedim Biotech SA's total assets have evolved over time, based on quarterly financial data. See DIM stock price and chart for real-time trading data and today's change.
Sartorius Stedim Biotech SA - Asset Composition Analysis
Sartorius Stedim Biotech SA Total Assets Breakdown (December 2025)
Sartorius Stedim Biotech SA total assets breakdown as of December 2025. Sartorius Stedim Biotech SA's total assets of €7.92 Billion consist of 18.0% current assets and 82.0% non-current assets. Explore Sartorius Stedim Biotech SA short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 5.3% |
| Accounts Receivable | €227.30 Million | 2.8% |
| Inventory | €690.90 Million | 8.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.54 Billion | 19.2% |
| Goodwill | €2.88 Billion | 36.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Sartorius Stedim Biotech SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sartorius Stedim Biotech SA's current assets represent 18.0% of total assets in 2025, a decrease from 53.2% in 2005.
- Cash Position: Cash and equivalents constituted 5.3% of total assets in 2025, up from 2.7% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 54.0% of total assets, an increase from 8.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 36.0% of total assets.
Sartorius Stedim Biotech SA Competitors by Total Assets
Key competitors of Sartorius Stedim Biotech SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Autek China Inc
SHE:300595
|
China | CN¥6.40 Billion |
|
Mingyue Optical Lens Co.Ltd.
SHE:301101
|
China | CN¥2.09 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
St.Shine Optical Co Ltd
TWO:1565
|
Taiwan | NT$7.81 Billion |
|
Interojo Inc
KQ:119610
|
Korea | ₩252.22 Billion |
|
Ocumetics Technology Corp
V:OTC
|
Canada | CA$1.15 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
Sartorius Stedim Biotech SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 1.91 | 1.48 |
| Quick Ratio | 0.55 | 1.18 | 0.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €186.30 Million | €861.00 Million | €449.20 Million |
Sartorius Stedim Biotech SA - Advanced Valuation Insights
This section examines the relationship between Sartorius Stedim Biotech SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.28 |
| Latest Market Cap to Assets Ratio | 2.27 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | €8.02 Billion |
| Market Capitalization | $18.18 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Sartorius Stedim Biotech SA's assets at a significant premium (2.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Sartorius Stedim Biotech SA's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Sartorius Stedim Biotech SA (2005–2025)
The table below shows the annual total assets of Sartorius Stedim Biotech SA from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €8.02 Billion ≈ $9.37 Billion |
-2.89% |
| 2024-12-31 | €8.26 Billion ≈ $9.65 Billion |
+6.67% |
| 2023-12-31 | €7.74 Billion ≈ $9.05 Billion |
+52.80% |
| 2022-12-31 | €5.07 Billion ≈ $5.92 Billion |
+28.20% |
| 2021-12-31 | €3.95 Billion ≈ $4.62 Billion |
+28.73% |
| 2020-12-31 | €3.07 Billion ≈ $3.59 Billion |
+68.61% |
| 2019-12-31 | €1.82 Billion ≈ $2.13 Billion |
+15.84% |
| 2018-12-31 | €1.57 Billion ≈ $1.84 Billion |
+11.93% |
| 2017-12-31 | €1.40 Billion ≈ $1.64 Billion |
+17.40% |
| 2016-12-31 | €1.20 Billion ≈ $1.40 Billion |
+12.17% |
| 2015-12-31 | €1.07 Billion ≈ $1.25 Billion |
+17.58% |
| 2014-12-31 | €906.76 Million ≈ $1.06 Billion |
+4.08% |
| 2013-12-31 | €871.23 Million ≈ $1.02 Billion |
+9.74% |
| 2012-12-31 | €793.87 Million ≈ $928.11 Million |
+10.16% |
| 2011-12-31 | €720.66 Million ≈ $842.53 Million |
+9.80% |
| 2010-12-31 | €656.34 Million ≈ $767.32 Million |
-1.73% |
| 2009-12-31 | €667.86 Million ≈ $780.80 Million |
+2.38% |
| 2008-12-31 | €652.34 Million ≈ $762.66 Million |
+1.81% |
| 2007-12-31 | €640.72 Million ≈ $749.07 Million |
+69.80% |
| 2006-12-31 | €377.34 Million ≈ $441.15 Million |
+4.09% |
| 2005-12-31 | €362.53 Million ≈ $423.83 Million |
-- |
About Sartorius Stedim Biotech SA
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more